Hormone use and risk for lung cancer: A pooled analysis from the International Lung Cancer Consortium (ILCCO)

A. C. Pesatori, M. Carugno, D. Consonni, R. J. Hung, A. Papadoupolos, M. T. Landi, H. Brenner, H. Müller, C. C. Harris, E. J. Duell, A. S. Andrew, J. R. McLaughlin, A. G. Schwartz, A. S. Wenzlaff, I. Stucker

Research output: Contribution to journalArticle

Abstract

Background:The association between oral contraceptive (OC) use, hormone replacement therapy (HRT) and lung cancer risk in women is still debated.Methods:We performed a pooled analysis of six case-control studies (1961 cases and 2609 controls) contributing to the International Lung Cancer Consortium. Potential associations were investigated with multivariable unconditional logistic regression and meta-analytic models. Multinomial logistic regressions were performed to investigate lung cancer risk across histologic types.Results:A reduced lung cancer risk was found for OC (odds ratio (OR)=0.81; 95% confidence interval (CI): 0.68-0.97) and HRT ever users (OR=0.77; 95% CI: 0.66-0.90). Both oestrogen only and oestrogen+progestin HRT were associated with decreased risk (OR=0.76; 95% CI: 0.61-0.94, and OR=0.66; 95% CI: 0.49-0.88, respectively). No dose-response relationship was observed with years of OC/HRT use. The greatest risk reduction was seen for squamous cell carcinoma (OR=0.53; 95% CI: 0.37-0.76) in OC users and in both adenocarcinoma (OR=0.79; 95% CI: 0.66-0.95) and small cell carcinoma (OR=0.37; 95% CI: 0.19-0.71) in HRT users. No interaction with smoking status or BMI was observed.Conclusion:Our findings suggest that exogenous hormones can play a protective role in lung cancer aetiology. However, given inconsistencies with epidemiological evidence from cohort studies, further and larger investigations are needed for a more comprehensive view of lung cancer development in women.

Original languageEnglish
Pages (from-to)1954-1964
Number of pages11
JournalBritish Journal of Cancer
Volume109
Issue number7
DOIs
Publication statusPublished - Oct 1 2013

Fingerprint

Lung Neoplasms
Odds Ratio
Hormones
Hormone Replacement Therapy
Confidence Intervals
Oral Contraceptives
Logistic Models
Estrogen Replacement Therapy
Small Cell Carcinoma
Risk Reduction Behavior
Case-Control Studies
Squamous Cell Carcinoma
Estrogens
Adenocarcinoma
Cohort Studies
Smoking

Keywords

  • exogenous hormones
  • hormone replacement therapy
  • lung cancer
  • oral contraceptives
  • pooled analysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hormone use and risk for lung cancer : A pooled analysis from the International Lung Cancer Consortium (ILCCO). / Pesatori, A. C.; Carugno, M.; Consonni, D.; Hung, R. J.; Papadoupolos, A.; Landi, M. T.; Brenner, H.; Müller, H.; Harris, C. C.; Duell, E. J.; Andrew, A. S.; McLaughlin, J. R.; Schwartz, A. G.; Wenzlaff, A. S.; Stucker, I.

In: British Journal of Cancer, Vol. 109, No. 7, 01.10.2013, p. 1954-1964.

Research output: Contribution to journalArticle

Pesatori, AC, Carugno, M, Consonni, D, Hung, RJ, Papadoupolos, A, Landi, MT, Brenner, H, Müller, H, Harris, CC, Duell, EJ, Andrew, AS, McLaughlin, JR, Schwartz, AG, Wenzlaff, AS & Stucker, I 2013, 'Hormone use and risk for lung cancer: A pooled analysis from the International Lung Cancer Consortium (ILCCO)', British Journal of Cancer, vol. 109, no. 7, pp. 1954-1964. https://doi.org/10.1038/bjc.2013.506
Pesatori, A. C. ; Carugno, M. ; Consonni, D. ; Hung, R. J. ; Papadoupolos, A. ; Landi, M. T. ; Brenner, H. ; Müller, H. ; Harris, C. C. ; Duell, E. J. ; Andrew, A. S. ; McLaughlin, J. R. ; Schwartz, A. G. ; Wenzlaff, A. S. ; Stucker, I. / Hormone use and risk for lung cancer : A pooled analysis from the International Lung Cancer Consortium (ILCCO). In: British Journal of Cancer. 2013 ; Vol. 109, No. 7. pp. 1954-1964.
@article{6fe8d08ef1e9403887e9d1082af8ee74,
title = "Hormone use and risk for lung cancer: A pooled analysis from the International Lung Cancer Consortium (ILCCO)",
abstract = "Background:The association between oral contraceptive (OC) use, hormone replacement therapy (HRT) and lung cancer risk in women is still debated.Methods:We performed a pooled analysis of six case-control studies (1961 cases and 2609 controls) contributing to the International Lung Cancer Consortium. Potential associations were investigated with multivariable unconditional logistic regression and meta-analytic models. Multinomial logistic regressions were performed to investigate lung cancer risk across histologic types.Results:A reduced lung cancer risk was found for OC (odds ratio (OR)=0.81; 95{\%} confidence interval (CI): 0.68-0.97) and HRT ever users (OR=0.77; 95{\%} CI: 0.66-0.90). Both oestrogen only and oestrogen+progestin HRT were associated with decreased risk (OR=0.76; 95{\%} CI: 0.61-0.94, and OR=0.66; 95{\%} CI: 0.49-0.88, respectively). No dose-response relationship was observed with years of OC/HRT use. The greatest risk reduction was seen for squamous cell carcinoma (OR=0.53; 95{\%} CI: 0.37-0.76) in OC users and in both adenocarcinoma (OR=0.79; 95{\%} CI: 0.66-0.95) and small cell carcinoma (OR=0.37; 95{\%} CI: 0.19-0.71) in HRT users. No interaction with smoking status or BMI was observed.Conclusion:Our findings suggest that exogenous hormones can play a protective role in lung cancer aetiology. However, given inconsistencies with epidemiological evidence from cohort studies, further and larger investigations are needed for a more comprehensive view of lung cancer development in women.",
keywords = "exogenous hormones, hormone replacement therapy, lung cancer, oral contraceptives, pooled analysis",
author = "Pesatori, {A. C.} and M. Carugno and D. Consonni and Hung, {R. J.} and A. Papadoupolos and Landi, {M. T.} and H. Brenner and H. M{\"u}ller and Harris, {C. C.} and Duell, {E. J.} and Andrew, {A. S.} and McLaughlin, {J. R.} and Schwartz, {A. G.} and Wenzlaff, {A. S.} and I. Stucker",
year = "2013",
month = "10",
day = "1",
doi = "10.1038/bjc.2013.506",
language = "English",
volume = "109",
pages = "1954--1964",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Hormone use and risk for lung cancer

T2 - A pooled analysis from the International Lung Cancer Consortium (ILCCO)

AU - Pesatori, A. C.

AU - Carugno, M.

AU - Consonni, D.

AU - Hung, R. J.

AU - Papadoupolos, A.

AU - Landi, M. T.

AU - Brenner, H.

AU - Müller, H.

AU - Harris, C. C.

AU - Duell, E. J.

AU - Andrew, A. S.

AU - McLaughlin, J. R.

AU - Schwartz, A. G.

AU - Wenzlaff, A. S.

AU - Stucker, I.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background:The association between oral contraceptive (OC) use, hormone replacement therapy (HRT) and lung cancer risk in women is still debated.Methods:We performed a pooled analysis of six case-control studies (1961 cases and 2609 controls) contributing to the International Lung Cancer Consortium. Potential associations were investigated with multivariable unconditional logistic regression and meta-analytic models. Multinomial logistic regressions were performed to investigate lung cancer risk across histologic types.Results:A reduced lung cancer risk was found for OC (odds ratio (OR)=0.81; 95% confidence interval (CI): 0.68-0.97) and HRT ever users (OR=0.77; 95% CI: 0.66-0.90). Both oestrogen only and oestrogen+progestin HRT were associated with decreased risk (OR=0.76; 95% CI: 0.61-0.94, and OR=0.66; 95% CI: 0.49-0.88, respectively). No dose-response relationship was observed with years of OC/HRT use. The greatest risk reduction was seen for squamous cell carcinoma (OR=0.53; 95% CI: 0.37-0.76) in OC users and in both adenocarcinoma (OR=0.79; 95% CI: 0.66-0.95) and small cell carcinoma (OR=0.37; 95% CI: 0.19-0.71) in HRT users. No interaction with smoking status or BMI was observed.Conclusion:Our findings suggest that exogenous hormones can play a protective role in lung cancer aetiology. However, given inconsistencies with epidemiological evidence from cohort studies, further and larger investigations are needed for a more comprehensive view of lung cancer development in women.

AB - Background:The association between oral contraceptive (OC) use, hormone replacement therapy (HRT) and lung cancer risk in women is still debated.Methods:We performed a pooled analysis of six case-control studies (1961 cases and 2609 controls) contributing to the International Lung Cancer Consortium. Potential associations were investigated with multivariable unconditional logistic regression and meta-analytic models. Multinomial logistic regressions were performed to investigate lung cancer risk across histologic types.Results:A reduced lung cancer risk was found for OC (odds ratio (OR)=0.81; 95% confidence interval (CI): 0.68-0.97) and HRT ever users (OR=0.77; 95% CI: 0.66-0.90). Both oestrogen only and oestrogen+progestin HRT were associated with decreased risk (OR=0.76; 95% CI: 0.61-0.94, and OR=0.66; 95% CI: 0.49-0.88, respectively). No dose-response relationship was observed with years of OC/HRT use. The greatest risk reduction was seen for squamous cell carcinoma (OR=0.53; 95% CI: 0.37-0.76) in OC users and in both adenocarcinoma (OR=0.79; 95% CI: 0.66-0.95) and small cell carcinoma (OR=0.37; 95% CI: 0.19-0.71) in HRT users. No interaction with smoking status or BMI was observed.Conclusion:Our findings suggest that exogenous hormones can play a protective role in lung cancer aetiology. However, given inconsistencies with epidemiological evidence from cohort studies, further and larger investigations are needed for a more comprehensive view of lung cancer development in women.

KW - exogenous hormones

KW - hormone replacement therapy

KW - lung cancer

KW - oral contraceptives

KW - pooled analysis

UR - http://www.scopus.com/inward/record.url?scp=84885174938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885174938&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.506

DO - 10.1038/bjc.2013.506

M3 - Article

C2 - 24002594

AN - SCOPUS:84885174938

VL - 109

SP - 1954

EP - 1964

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -